CA2846758C - Triazolopyridine compounds as pde10a inhibitors - Google Patents

Triazolopyridine compounds as pde10a inhibitors Download PDF

Info

Publication number
CA2846758C
CA2846758C CA2846758A CA2846758A CA2846758C CA 2846758 C CA2846758 C CA 2846758C CA 2846758 A CA2846758 A CA 2846758A CA 2846758 A CA2846758 A CA 2846758A CA 2846758 C CA2846758 C CA 2846758C
Authority
CA
Canada
Prior art keywords
pyridin
methyl
triazolo
pyrazole
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2846758A
Other languages
English (en)
French (fr)
Other versions
CA2846758A1 (en
Inventor
Alexander Flohr
Katrin Groebke Zbinden
Matthias Koerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2846758(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2846758A1 publication Critical patent/CA2846758A1/en
Application granted granted Critical
Publication of CA2846758C publication Critical patent/CA2846758C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2846758A 2011-09-19 2012-09-17 Triazolopyridine compounds as pde10a inhibitors Expired - Fee Related CA2846758C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11181752 2011-09-19
EP11181752.4 2011-09-19
PCT/EP2012/068203 WO2013041472A1 (en) 2011-09-19 2012-09-17 Triazolopyridine compounds as pde10a inhibitors

Publications (2)

Publication Number Publication Date
CA2846758A1 CA2846758A1 (en) 2013-03-28
CA2846758C true CA2846758C (en) 2017-09-12

Family

ID=46851999

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2846758A Expired - Fee Related CA2846758C (en) 2011-09-19 2012-09-17 Triazolopyridine compounds as pde10a inhibitors

Country Status (19)

Country Link
US (2) US8946427B2 (enExample)
EP (1) EP2758396B1 (enExample)
JP (1) JP2014526533A (enExample)
KR (1) KR101584925B1 (enExample)
CN (1) CN103827114B (enExample)
AU (1) AU2012311713A1 (enExample)
BR (1) BR112014006248A2 (enExample)
CA (1) CA2846758C (enExample)
CL (1) CL2014000641A1 (enExample)
CO (1) CO6900144A2 (enExample)
EA (1) EA201490599A1 (enExample)
ES (1) ES2626801T3 (enExample)
IL (1) IL231403A0 (enExample)
MX (1) MX2014003025A (enExample)
PE (1) PE20141553A1 (enExample)
PH (1) PH12014500499A1 (enExample)
SG (1) SG11201400759RA (enExample)
UA (1) UA108711C2 (enExample)
WO (1) WO2013041472A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en) * 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
CN105164126B (zh) * 2013-04-30 2017-05-31 豪夫迈·罗氏有限公司 吡唑酰胺的Pd‑催化偶联
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
KR20170032328A (ko) * 2014-07-30 2017-03-22 모찌다 세이야쿠 가부시끼가이샤 피라졸 유도체의 제조 방법
CA2956268A1 (en) * 2014-07-30 2016-02-04 Mochida Pharmaceutical Co., Ltd. Pyrazole derivative manufacturing method
CN107635984B (zh) 2015-03-11 2021-04-13 Fmc公司 杂环取代的二环唑杀有害生物剂
KR102536024B1 (ko) 2015-03-12 2023-05-24 에프엠씨 코포레이션 헤테로환-치환 이환 아졸 살충제
BR112018007034B1 (pt) 2015-10-08 2022-10-11 Fmc Corporation Composto, composição, método para controlar uma praga de invertebrados e semente revestida
EP3672966B1 (de) * 2017-08-22 2022-09-21 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
US12116370B2 (en) 2019-05-27 2024-10-15 Nihon Nohyaku Co., Ltd. Condensed heterocyclic compound having a bridgehead nitrogen atom or salt thereof, agricultural or horticultural insecticide comprising the compound, and method for using the insecticide
AR119140A1 (es) 2019-06-13 2021-11-24 Pi Industries Ltd Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas
CN110396157B (zh) * 2019-08-07 2021-07-30 广州市建筑科学研究院有限公司 缓释型聚羧酸纳米减水剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP2348018A4 (en) * 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE
WO2010059836A1 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2417135A1 (en) * 2009-04-07 2012-02-15 Schering Corporation Substituted triazolopyridines and analogs thereof
MX2012003469A (es) * 2009-09-24 2012-04-19 Hoffmann La Roche Derivados de imidazopiridina o imidazopirimidina como inhibidores fosfodiesterasa 10a.
CN102696239B (zh) 2009-11-24 2020-08-25 诺基亚技术有限公司 一种设备
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TW201200516A (en) * 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors

Also Published As

Publication number Publication date
WO2013041472A1 (en) 2013-03-28
NZ621597A (en) 2015-04-24
UA108711C2 (uk) 2015-05-25
US9227970B2 (en) 2016-01-05
CN103827114A (zh) 2014-05-28
JP2014526533A (ja) 2014-10-06
SG11201400759RA (en) 2014-07-30
EP2758396B1 (en) 2017-03-29
US20150099735A1 (en) 2015-04-09
MX2014003025A (es) 2014-05-28
EA201490599A1 (ru) 2014-07-30
KR20140075716A (ko) 2014-06-19
CO6900144A2 (es) 2014-03-20
PH12014500499A1 (en) 2014-04-14
EP2758396A1 (en) 2014-07-30
ES2626801T3 (es) 2017-07-26
US8946427B2 (en) 2015-02-03
IL231403A0 (en) 2014-04-30
CA2846758A1 (en) 2013-03-28
KR101584925B1 (ko) 2016-01-12
PE20141553A1 (es) 2014-10-30
AU2012311713A1 (en) 2014-03-13
CL2014000641A1 (es) 2014-11-14
CN103827114B (zh) 2016-08-24
US20140303141A1 (en) 2014-10-09
BR112014006248A2 (pt) 2017-04-11

Similar Documents

Publication Publication Date Title
US9227970B2 (en) Triazolopyridine compounds
US8470820B2 (en) Nitrogen-containing heteroaryl derivatives
EP2649070B1 (en) Triazolopyridine compounds
EP2480546B1 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors
EP2753604B1 (en) Pde10 modulators
EP2601192B1 (en) Fused heterocyclic compounds
US9540384B2 (en) Pyrrolidino heterocycles
US8883788B2 (en) Fused heterocyclic ring compound
NZ621597B2 (en) Triazolopyridine compounds as pde10a inhibitors
US10399985B2 (en) (Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders
HK1193595A (en) Triazolopyridine compounds as pde10a inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140226

MKLA Lapsed

Effective date: 20190917